Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Vestcor Inc

Vestcor Inc lowered its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 53.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,865 shares of the biopharmaceutical company's stock after selling 32,566 shares during the quarter. Vestcor Inc's holdings in Catalyst Pharmaceuticals were worth $582,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of CPRX. GSA Capital Partners LLP acquired a new stake in shares of Catalyst Pharmaceuticals in the third quarter valued at about $625,000. Victory Capital Management Inc. grew its stake in shares of Catalyst Pharmaceuticals by 5.8% in the third quarter. Victory Capital Management Inc. now owns 291,505 shares of the biopharmaceutical company's stock valued at $5,795,000 after buying an additional 15,996 shares in the last quarter. Natixis Advisors LLC grew its stake in shares of Catalyst Pharmaceuticals by 37.7% in the third quarter. Natixis Advisors LLC now owns 45,637 shares of the biopharmaceutical company's stock valued at $907,000 after buying an additional 12,491 shares in the last quarter. Quest Partners LLC grew its stake in shares of Catalyst Pharmaceuticals by 36,146.6% in the third quarter. Quest Partners LLC now owns 37,334 shares of the biopharmaceutical company's stock valued at $742,000 after buying an additional 37,231 shares in the last quarter. Finally, Segall Bryant & Hamill LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the third quarter valued at about $808,000. Institutional investors and hedge funds own 79.22% of the company's stock.

Insider Buying and Selling

In related news, insider Gary Ingenito sold 44,904 shares of the firm's stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total value of $991,929.36. Following the sale, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,521,404.57. This trade represents a 39.47 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $22.98, for a total value of $1,447,165.50. Following the completion of the sale, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. This trade represents a 25.04 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 11.00% of the company's stock.

Remove Ads

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX traded up $0.56 during mid-day trading on Thursday, hitting $23.16. The company had a trading volume of 1,092,935 shares, compared to its average volume of 1,044,002. The stock has a market cap of $2.81 billion, a price-to-earnings ratio of 19.63, a PEG ratio of 3.31 and a beta of 0.84. Catalyst Pharmaceuticals, Inc. has a 12 month low of $14.47 and a 12 month high of $24.64. The firm's 50 day simple moving average is $22.34 and its two-hundred day simple moving average is $21.57.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on CPRX. HC Wainwright reiterated a "buy" rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, February 28th. StockNews.com raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, February 28th. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Robert W. Baird increased their price target on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, March 3rd. Finally, Stephens reissued an "overweight" rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a report on Thursday, February 27th. Eight equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Catalyst Pharmaceuticals presently has an average rating of "Buy" and a consensus price target of $32.50.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.